Meridian Wealth Management LLC Boosts Stock Position in Immutep Limited (NASDAQ:IMMP)

Meridian Wealth Management LLC lifted its holdings in shares of Immutep Limited (NASDAQ:IMMP) by 4.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 398,450 shares of the biotechnology company’s stock after buying an additional 17,250 shares during the quarter. Meridian Wealth Management LLC owned approximately 0.27% of Immutep worth $881,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in IMMP. XY Capital Ltd lifted its stake in Immutep by 108.3% in the 3rd quarter. XY Capital Ltd now owns 108,349 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 56,344 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Immutep in the second quarter worth approximately $26,000. Virtu Financial LLC increased its position in shares of Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Immutep by 15.4% in the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 4,700 shares during the last quarter. Institutional investors and hedge funds own 2.32% of the company’s stock.

Immutep Trading Up 4.6 %

IMMP stock opened at $1.93 on Friday. The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average of $2.03 and a two-hundred day moving average of $2.29. Immutep Limited has a 12 month low of $1.66 and a 12 month high of $3.34.

Wall Street Analyst Weigh In

Separately, Robert W. Baird lifted their target price on shares of Immutep from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Friday, November 15th.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.